Öner, NKaya, MKarasalihoglu, SKaraca, HÇeltik, CTütüncüler, F2024-06-122024-06-1220041034-48101440-1754https://doi.org/10.1111/j.1440-1754.2004.00431.xhttps://hdl.handle.net/20.500.14551/19236Objective: The aim of this study was to evaluate bone mineral density (BMD) in epileptic children receiving valproic acid (VPA) and to determine differences between osteopenic and non-osteopenic children. Methods: Thirty-three epileptic children, receiving VPA for at least 6 months, were compared with 33 healthy children for BMD. BMD was measured by dual-energy X-ray absorptiometry at lumbar vertebrae, femoral neck and greater trochanter. Serum calcium, phosphorus, alkaline phosphates, osteocalcin and VPA levels were also determined. Results: Patient's osteocalcin levels were significantly higher (P = 0.02) and femur and trochanter BMD values were significantly lower (P = 0.04 and P = 0.03, respectively). Duration of VPA therapy was significantly longer and doses of VPA were significantly higher in seven osteopenic patients compared with 26 non-osteopenic patients. Osteopenic patients (4.6 +/- 2.4 years) were younger than non-osteopenic patients (7.8 +/- 3.2 years) (P = 0.01). Conclusion: Long-term and high dose VPA therapy may cause osteopenia, primarily in younger epileptic children. These patients should be followed closely by BMD measurements.en10.1111/j.1440-1754.2004.00431.xinfo:eu-repo/semantics/closedAccessBone Mineral DensityDual-Energy X-Ray AbsorptiometryOsteocalcinValproic AcidTerm Anticonvulsant TherapyX-Ray AbsorptiometryAntiepileptic DrugsCalcium-MetabolismDensityCarbamazepineArticle408470473Q3WOS:0002226823000122-s2.0-404313169715265190Q2